The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@thinshins great comment about activ2 if uk home trial fails to provide positive results. I said at the start of the year this was looking like a September play here and it is probably about right.
Couple of good articles: https://www.bbc.co.uk/news/health-52354520
https://www.bbc.co.uk/news/health-55639096
Second one mentions Alexandra Constantin also little video of RM.
GLA
I agree MrCosts, it really is a shame that it is taking this long to progress even though we are a UK company, with UK trials backed by UK health authorities, yet we are still away off from EUA, on top of this it seems that sentiment has shifted dramatically in regards to home trial results being inconclusive due to not a strong enough signal to demonstrate efficacy.
Mainstream media will likely portray this as negative and further damage the SP as we were all expecting results better than the hospital Arm due to the belief IFN is more effective early.
We will then be clutching at Activ2 as our phase 3 is no where near close to completing recruitment.
Even then I'm not sure how we will hold up in activ2, seeing as the cohort is open for anyone above 18 who has tested positive. (not targeted to people with co-morbidities or IFN deficiencies), how do you guys and girls see activ2 playing out after the recent "putting out fires" comment by RM?
I really was buzzing hoping our drug would treat thousands here in the UK and abroad and be part of it by investing.
Please do correct me on any misunderstanding I may have, thanks.
Mrcost I feel the same. With all the positive news we had during January and February I didn't except sp to be 1.49. Still holding for gold
I bloody hope so, I am fed up with waiting for news. People will say just sell up etc however I don't want to sell up I just want some news on what is happening. A few on here trying to play it cool, no one is ever happy watching the SP just fall away week by week.
I am not deramper just because I am having a moan, I am LTH having a moan and yes I feel better for it!
It will be some feat if RM can sort a UK trial, worldwide P3 trial and Activ2 and fail to obtain approval and orders. It sounds like the science is strong therefore approval / orders should follow.
These statements are often written by robots - best to ignore.
I have just looked at the 'asktraders.com' Synairgen article kindly supplied by a contributor to this thread. As well as the obvious "sitting on the fence" conclusion drawn as a consequence of a study of the trading pattern, some of the statements in the article raise questions about the author's knowledge about the subject of their article.
1. "If the phase II trial is successful, we will likely get a surge in Synairgen’s share price after the UK health regulators allow the drug to proceed to phase III trials. This trial’s success will help keep most COVID-19 patients out of hospitals as they will be treated and recover from the comfort of their homes."
The author is apparently unaware that the extensive Phase III trials in multiple countries are already well established. Additionally there appears to be confusion between the already peer-reviewed hospital trials, and the home trials, from which we are currently expecting feedback.
2. "Synairgen is simultaneously running phase II clinical trials of its SNG001 drug to treat chronic obstructive pulmonary disease (COPD), a prevalent disease among smokers with a very high mortality rate."
Partly true, although the COPD clinical trials were placed on hold some time ago so that the company could trial their product with Covid-19 patients.
In my view, the author has hurriedly written this piece with the minimum of research, so that the article is both confusing and inconclusive. Please feel free to correct me should you disagree with my interpretation.
Finally, I am disappointed that there are so many free online articles of a similar quality to this one. I fail to see how they benefit potential investors?
I wish your comment was clear .
The author doesn’t seem to have a clue - junk article
"....An experienced team of researchers has led the firm since being was spun off from the University of Southampton..."
Being was spun off from the University of Southampton. Something with the do with the creation of the Universe? It all started in Southampton. Everything is clear now.
Haha - well I do sincerely hope we have a severed bullish breakout before too long. I know al the factors required but I only have two shares in my portfolio atm and I've so far favoured the wrong one with my allocation! The other one is on a quite sharp rise (but I've probably missed the best of it for now) so although it's making up for this one, I've had impure thoughts about shifting some from this to the other. I just know the second I do will be when the other decides to dip and this takes off, so I'm sitting firm.
"SNG shares are trading almost flat for the year"
That's a hell of a rollercoaster kind of 'flat'!
Fortunately my cat's non-triangular so only predicts mono-directional bull breakouts - or should that be breakouts of bull....?
"formed a triangle pattern that could lead to a breakout in either direction"
Even my cat could have predicted that :-)
https://www.asktraders.com/analysis/synairgen-shares-are-trading-almost-flat-for-the-year-but-seem-ready-to-breakout/
Today posted.
Day 90 for the final patient is Monday next week so not long to go now......